ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "a78c4684-1f83-4ab6-b14e-ca57c41d9270"}, "_deposit": {"created_by": 17, "id": "19148", "owners": [17], "pid": {"revision_id": 0, "type": "depid", "value": "19148"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00019148", "sets": []}, "author_link": ["55967"], "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "17", "bibliographicPageStart": "7", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "FLT3, a type III receptor tyrosine kinase, expresses on most acute leukemia cells as well as normal hematopoietic stem/progenitor cells. Mutation in the FLT3 gene is the most frequent genetic alteration in acute myeloid leukemia (AML) and is well known as an important driver mutation for the development of myeloid malignancies. FLT3 mutation is a strong poor prognostic factor for the long-term survival in AML patients, while neither high-dose chemotherapy nor allogeneic hematopoietic stem cell transplantation can overcome a poor prognosis. Development of an FLT3 inhibitor is, therefore, much awaited. To date, several potent FLT3 inhibitors have been developed and some of them were evaluated for efficacy in clinical trials, although no FLT3 inhibitor has been yet approved. Moreover, several problems for clinical use, such as adverse effects, blood concentration and resistance have been apparent. Recently developed AC220 is a highly selective and sensitive FLT3 inhibitor. In Phase I and II trials, AC220 so far showed the best efficacy of AML cells harboring FLT3 mutation among clinically evaluated FLT3 inhibitors, while severe bone marrow suppression and QTc prolongation should be resolved for the clinical use. In this review, I summarize the characteristics of FLT3 inhibitors in clinical development and discuss important issues to be resolved for clinical use.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/21254"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.77.1-2.7", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7712.html", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "KIYOI, HITOSHI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "55967", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "02_Kiyoi.pdf", "filesize": [{"value": "566.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 566500.0, "url": {"label": "02_Kiyoi.pdf", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/19148/files/02_Kiyoi.pdf"}, "version_id": "86d3af26-cfe8-4c93-b1e6-b37fc512c2d3"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "FLT3", "subitem_subject_scheme": "Other"}, {"subitem_subject": "inhibitors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "molecular target", "subitem_subject_scheme": "Other"}, {"subitem_subject": "resistance", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "FLT3 Inhibitors: Recent Advances and Problems for Clinical Application", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "FLT3 Inhibitors: Recent Advances and Problems for Clinical Application", "subitem_title_language": "en"}]}, "item_type_id": "9", "owner": "17", "path": ["1674"], "permalink_uri": "https://doi.org/10.18999/nagjms.77.1-2.7", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2015-02-26"}, "publish_date": "2015-02-26", "publish_status": "0", "recid": "19148", "relation": {}, "relation_version_is_last": true, "title": ["FLT3 Inhibitors: Recent Advances and Problems for Clinical Application"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 77(1-2)

FLT3 Inhibitors: Recent Advances and Problems for Clinical Application

https://doi.org/10.18999/nagjms.77.1-2.7
https://doi.org/10.18999/nagjms.77.1-2.7
8a68dba0-e83f-472c-bfa0-5acf6f692b23
名前 / ファイル ライセンス アクション
02_Kiyoi.pdf 02_Kiyoi.pdf (566.5 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-02-26
タイトル
タイトル FLT3 Inhibitors: Recent Advances and Problems for Clinical Application
言語 en
著者 KIYOI, HITOSHI

× KIYOI, HITOSHI

WEKO 55967

en KIYOI, HITOSHI

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
キーワード
主題Scheme Other
主題 FLT3
キーワード
主題Scheme Other
主題 inhibitors
キーワード
主題Scheme Other
主題 leukemia
キーワード
主題Scheme Other
主題 molecular target
キーワード
主題Scheme Other
主題 resistance
抄録
内容記述 FLT3, a type III receptor tyrosine kinase, expresses on most acute leukemia cells as well as normal hematopoietic stem/progenitor cells. Mutation in the FLT3 gene is the most frequent genetic alteration in acute myeloid leukemia (AML) and is well known as an important driver mutation for the development of myeloid malignancies. FLT3 mutation is a strong poor prognostic factor for the long-term survival in AML patients, while neither high-dose chemotherapy nor allogeneic hematopoietic stem cell transplantation can overcome a poor prognosis. Development of an FLT3 inhibitor is, therefore, much awaited. To date, several potent FLT3 inhibitors have been developed and some of them were evaluated for efficacy in clinical trials, although no FLT3 inhibitor has been yet approved. Moreover, several problems for clinical use, such as adverse effects, blood concentration and resistance have been apparent. Recently developed AC220 is a highly selective and sensitive FLT3 inhibitor. In Phase I and II trials, AC220 so far showed the best efficacy of AML cells harboring FLT3 mutation among clinically evaluated FLT3 inhibitors, while severe bone marrow suppression and QTc prolongation should be resolved for the clinical use. In this review, I summarize the characteristics of FLT3 inhibitors in clinical development and discuss important issues to be resolved for clinical use.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Nagoya University School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.77.1-2.7
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7712.html
ISSN(print)
収録物識別子タイプ PISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ EISSN
収録物識別子 2186-3326
書誌情報 en : Nagoya Journal of Medical Science

巻 77, 号 1-2, p. 7-17, 発行日 2015-02
著者版フラグ
値 publisher
URI
識別子 http://hdl.handle.net/2237/21254
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 12:37:57.620971
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3